吉利德科学高管近日透露，公司已正式向美国食品药品监督管理局（FDA）提交嵌合抗原受体T细胞疗法Anito-Cel的上市申请。目前正等待监管机构发出受理确认函，预计将于本季度内收到相关通知。若审批进展顺利，该疗法计划于2026年下半年正式推向市场。
吉利德科学高管近日透露，公司已正式向美国食品药品监督管理局（FDA）提交嵌合抗原受体T细胞疗法Anito-Cel的上市申请。目前正等待监管机构发出受理确认函，预计将于本季度内收到相关通知。若审批进展顺利，该疗法计划于2026年下半年正式推向市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.